

Abstracts presented at the
*13th International Workshop on Adverse Drug Reactions
and Co-morbidities in HIV*

Rome, Italy, 14–16 July 2011

ORGANIZING COMMITTEE

Chairs for 2011

Kathleen Mulligan	University of California at San Francisco, CA, USA
Peter Reiss	University of Amsterdam, Amsterdam, the Netherlands
Giovanni Guaraldi	University of Modena, Modena, Italy
Andrew Carr	St Vincent's Hospital, Sydney, Australia
Jacqueline Capeau	Faculty of Medicine Saint Antoine, INSERM, Paris, France
David Cooper	University of New South Wales, Sydney, Australia
Stefan Mauss	Center for HIV and Hepatogastroenterology, Düsseldorf, Germany
Morrie Schambelan	University of California at San Francisco, CA, USA
Ian Weller	University College London Medical School, London, UK

SCIENTIFIC COMMITTEE

Georg Behrens	Medical School of Hannover, Hannover, Germany
Todd Brown	Johns Hopkins University, Baltimore, MD, USA
Judith Currier	University of California, Los Angeles, CA, USA
Gregory Dore	University of New South Wales, Sydney, Australia
Michael Dubé	University of Southern California, Los Angeles, CA, USA
Julian Falutz	Immune Deficiency Treatment Center, Montreal General Hospital, Montreal, Canada
Steve Grinspoon	Massachusetts General Hospital, Boston, MA, USA
Carl Grunfeld	University of California Medical Center, San Francisco, CA, USA
Donald Kotler	Columbia University, New York, NY, USA
Jules Levin	The National AIDS Treatment Advocacy Project, New York, NY, USA
Jens Lundgren	University of Copenhagen, Hvidovre, Denmark
Esteban Martínez	IDIPAPS - Hospital Clinic, University of Barcelona, Barcelona, Spain
Veronica Miller	The George Washington University, Washington, DC, USA
Graeme Moyle	Chelsea and Westminster Hospital, London, UK
Robert Munk	AIDS INFO NET, Arroyo Seco, NM, USA
Bill Powderly	University College, Dublin, Ireland
Massimo Puoti	University Hospital, Brescia, Italy
Willy Rozenbaum	Hôpital Tenon, Université Pierre et Marie Curie, Paris, France
Pablo Tebas	University of Pennsylvania, Philadelphia, PA, USA
Sharon Walmsley	University Health Network, Toronto, Canada
Heiner Wedemeyer	Hannover Medical School, Hannover, Germany
Kevin Yarasheski	Washington University, St Louis, MO, USA

PLENARY SPEAKERS

Paola Cinque	San Raffaele Scientific Institute, Milan, Italy
Göran Hansson	Karolinska Institutet, Stockholm, Sweden
Jan Hoeijmakers	Erasmus University Medical Center, Rotterdam, the Netherlands
Tom Hostetter	Albert Einstein College of Medicine, New York, USA
Robert Ross	Queen's University, Kingston, Ontario, Canada
George Schett	University of Erlangen-Nuremberg, Erlangen, Germany

ORGANIZING SECRETARIAT

International Medical Press	36 St Mary at Hill London EC3R 8DU, UK Tel: +44 20 7398 0700 Fax: +44 20 7398 0701 www.intmedpress.com E-mail: lipodystrophy@intmedpress.com
-----------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------



ABSTRACT CONTENTS

PAGE	TITLE AND PRESENTING AUTHOR	ABSTRACT
ORAL PRESENTATIONS		
Session 1		
A3	Application of 16S ribosomal RNA gene-targeted pyrosequencing to investigate the consequence of HIV disease and antiviral therapy on the gut microbiome: a microbial (meta)genomic snapshot of duodenal biopsies, luminal aspirates, and stool pre- and post-treatment <i>CL Ellis</i>	001
A3	Microbial translocation and metabolic and morphologic measures in treated and untreated HIV infection <i>MP Dubé</i>	002
A4	Tauroursodeoxycholic acid ameliorates ritonavir-induced ER stress and insulin resistance <i>DN Reeds</i>	003
A5	Abnormal reduction in serum FGF19 levels and in the expression of receptors for FGF19/FGF21 in adipose tissue from HIV-infected patients <i>F Villarroya</i>	004
Session 2		
A5	Plasma markers of bone loss and bone formation decrease with intermittent antiretroviral therapy and predict change in bone mineral density <i>J Hoy</i>	005
A6	Lower fat mass and lower bone formation predict greater bone loss with tenofovir in HIV-infected adults <i>A Carr</i>	006
A7	Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents <i>R Bedimo</i>	007
A7	Prevalence and risk factors of subclinical vertebral fractures in a cohort of HIV positive patients <i>K Luzi</i>	008
Session 3		
A8	Bone mineral density (BMD) analysis in antiretroviral (ART)-naïve subjects taking lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC) for 96 weeks in the PROGRESS Study <i>RB Qaqish</i>	009
A9	Traditional risk factors overshadow HIV-related factors in predicting vitamin D deficiency in HIV-infected children and young adults <i>AC Ross</i>	010

PAGE	TITLE AND PRESENTING AUTHOR	ABSTRACT
A9	Safety and efficacy of once-monthly dosing of vitamin D3 (50,000 IU) in HIV-infected youth: Adolescent Trials Network Study 063 <i>K Mulligan</i>	011
	Session 4	
A10	HIV-infected patients exhibit a worse cardiovascular risk profile after a first episode of acute coronary syndrome. Final results of long term follow up in the PACS-HIV study <i>F Boccara</i>	012
A11	Antiretroviral therapy can be associated with increase in LDL apolipoprotein-B residence time without increase in LDL-apo-B oxidation and glycation <i>S Das</i>	013
A12	Association of different lipid measures for atherogenic lipid fractions and risk of coronary events in patients receiving combination antiretroviral therapy: the Swiss HIV Cohort Study <i>HC Bucher</i>	014
A13	How much do smoking, hypertension and diabetes contribute to acute coronary syndrome in HIV-infected patients relative to uninfected patients? <i>M Calvo-Sánchez</i>	015
A14	Changes in biomarkers in HIV-1-infected treatment-naive subjects treated with tenofovir DF/emtricitabine plus atazanavir/ritonavir or lopinavir/ritonavir for 96 weeks: the CASTLE biomarker substudy <i>G Moyle</i>	016
	Session 5	
A14	Development of a definition for rapid progression of renal disease in HIV-positive persons <i>L Ryom</i>	017
A15	Renal disease in HIV-infected children and adolescents participating in the LEGACY cohort, United States, 2001–2006 <i>AF Camacho-Gonzalez</i>	018
A16	Impact of tenofovir-associated renal dysfunction among HIV-infected patients with low body-weight: a retrospective cohort study of the Japanese patients <i>T Nishijima</i>	019
A17	Effect on renal function of tenofovir co-administered with either efavirenz or boosted lopinavir or boosted atazanavir: the Swiss HIV Cohort Study <i>HC Bucher</i>	020
	Session 6	
A18	Raltegravir as replacement for PI- or NNRTI-based ART in HIV-infected women with lipohypertrophy: The Women, Integrase, and Fat Accumulation Trial <i>JE Lake</i>	021
A18	Surrogate markers of visceral adipose tissue (VAT) in HIV-infected males: how accurate are they? <i>J Falutz</i>	022

PAGE	TITLE AND PRESENTING AUTHOR	ABSTRACT
A19	Results from the pooled DEXA substudies of the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults <i>P Tebas</i>	O23
A20	The influence of HLA supertype on thymidine analogue induced body composition changes in STEAL <i>DV Cordery</i>	O24
POSTER PRESENTATIONS		
Adipocyte biology		
A25	Lipomatosis in HIV-1-infected patients: comparative analysis of the molecular signature in 'buffalo hump' and lipomas at distinct anatomical sites <i>M Giralt</i>	P01
Aging & associated disorders		
A27	Cost of non-infectious co-morbidities in patients with HIV <i>G Guaraldi</i>	P02
A27	Premature decline of serum total testosterone in human immunodeficiency virus (HIV) infected men with HIV-related lipodystrophy in the highly active antiretroviral therapy (HAART) era: a cross-sectional observational study <i>G Guaraldi</i>	P03
A28	Prevalence of sarcopenia defined by skeletal muscle mass and function in an urban cohort of older HIV-infected patients under care <i>P Wasserman</i>	P04
Body composition		
A29	Longitudinal relationships between self-reported body fat changes and physical and mental health-related quality of life in the Multicenter AIDS Cohort Study (MACS) <i>TT Brown</i>	P05
A29	Metabolic risk factors in responders to tesamorelin, a growth hormone-releasing factor (GRF) analogue, in HIV-infected patients with excess abdominal fat <i>J Falutz</i>	P06
A30	Coronary artery calcification is associated with femoral but not with lumbar spine mineral density <i>G Guaraldi</i>	P07
A31	The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial <i>JE Lake</i>	P08
A31	Peripheral intermuscular adipose tissue and intramyocellular lipids: other fat compartments implicated in HIV-associated lipodystrophy changes seen on switching from thymidine analogues to tenofovir <i>A Milinkovic</i>	P09
A32	Lipodystrophy, is it still relevant? <i>J Price</i>	P10

Table 1. (Abstract P06)

	Week 26	Week 52
VAT (%)	-27.4 (14.0) vs 9.8 (14.9) ¹	-31.1 (16.8) vs 8.1 (13.8) ¹
WC (cm)	-4.2 (5.7) vs -0.4 (4.4)*	-4.7 (6.4) vs -1.0 (4.9)*
TG (mg/dl)	-50 (147) vs -12 (105)*	-68 (159) vs 3 (102)*
IGF-I (ng/ml)	136 (106) vs 85 (104)*	91 (100) vs 76 (138)
FBG (mg/dl)	1 (16) vs 5 (14)*	-1 (14) vs 8 (17)*
Insulin (μ U/ml)	-1.0 (24.7) vs 5.6 (13.2)*	-2.5 (18.7) vs 4.8 (17.5)*
HbA1c (%)	0.07 (0.34) vs 0.27 (0.41)*	0.03 (0.32) vs 0.18 (0.46)*

Data are mean (sd). * $P < 0.05$. ¹Analysis not done.

Method: Two Phase III multicenter, randomized, double-blind, trials, consisting of 26-week, placebo-controlled primary intervention phase followed by 26-week extension phase were conducted. Data from the two studies were pooled. In the per-protocol population, 402 HIV patients with excess abdominal fat were treated with tesamorelin for the main phase (26 weeks) and 176 patients for both phases (52 weeks). Statistical analyses were performed on combined results from the two trials using ANCOVA models for efficacy and some safety parameters.

Results: Dropout rates were similar in treatment and placebo groups. At week 26, 68.8% ($n=232$) of tesamorelin-treated patients vs 32.6% ($n=56$) of placebo-treated patients were categorized as responders ($P < 0.001$). 72.4% of patients treated with tesamorelin for 52 weeks were categorized as responders. Changes from baseline (mean [standard deviation]) in tesamorelin-treated responders versus non-responders are shown in Table 1 for the main and the extension phases.

Distress due to belly image as assessed by patients was also improved in VAT responders at week 26 (score change: 15.53 vs 3.40 [$P < 0.001$]). FBG and insulin were unchanged in responders and deteriorated in non-responders.

Conclusion: This analysis revealed a significantly greater responder rate in tesamorelin-treated patients compared to placebo. FBG and insulin were unchanged in the responders but deteriorated in non-responders. These data show that no clinically significant changes in glucose parameters occurred in the large majority of HIV patients with excess abdominal fat responding to tesamorelin, with significant reductions in VAT. Moreover, significant benefits in metabolic risk factors accrued. These data provide important new evidence for the clinical utility and metabolic benefits of strategies to reduce VAT by augmenting the biological secretion of GH.

ABSTRACT P07

Antiviral Therapy 2011; 16 Suppl 2:A30

Coronary artery calcification is associated with femoral but not with lumbar spine mineral density

A Bellasi¹, S Zona², G Orlando², F Carli², S Cocchi², G Ligabue³, V Richira⁴, P Bagni², P Raggi⁵, G Guaraldi²

¹Nephrology, Dialysis and Hypertension Department, S Orsola-Malpighi, Bologna, Italy; ²Metabolic Clinic, Infectious and Tropical Diseases Unit, Department of Medicine, University of Modena and Reggio Emilia, Modena, Italy; ³Radiology Unit, Department of Imaging, University of Modena and Reggio Emilia, Modena, Italy; ⁴Division of Endocrinology, Department of Emergency Medicine, University of Modena and Reggio Emilia, Modena, Italy; ⁵Division of Cardiology, Department of Medicine, Emory University, Atlanta, GA, USA

Background: Vascular calcification (VC) of the coronaries (CAC) is associated with a high risk of cardiovascular (CV) events and poor survival. A large body of evidence suggests the existence of a link between bone demineralization and VC. We aimed at testing the association between CAC and bone mineral density (BMD) in a large cohort of HIV-infected patients.

Materials: We assessed simultaneously CAC as well as lumbar and femoral BMD in a large cohort of 681 consecutive HIV-infected patients by means of cardiac CT and DEXA. Logistic regression analysis was used to determine the association between low femoral and lumbar spine BMD (defined as BMD below the 25th percentile of the study cohort distribution) and extensive CAC (defined as CAC greater than 100 Agatston Unit)

Results: Patients with CAC > 100 were older, more likely to be male, diabetic and overweight. In contrast, a better renal function and a lower CV risk profile was noted among patients without extensive CAC < 100. At univariable analyses, a trend toward low femoral (14.26 vs 22.6, $P = 0.10$) but not lumbar spine BMD (15 vs 16, $P = 0.95$) was noted. Adjustments for factors associated with either

CAC or BMD revealed a significant association between CAC and femoral but not lumbar spine BMD. Indeed, patients with extensive CAC had a twofold higher risk of having a low femoral BMD (OR: 2.24; 95% CI: 1.08–4.65; $P=0.03$) after adjustment for age, sex, diabetes, BMI, Framingham risk score, estimated glomerular filtration rate (by EPI equation), protease inhibitor exposure and CD4 nadir.

Conclusion: Current results show that CAC is independently associated with low BMD in HIV infected patients. Further studies are needed to elucidate the mechanisms that link bone demineralization and VC deposition and whether therapies that impact BMD might also attenuate VC progression in HIV-infected patients.

ABSTRACT P08

Antiviral Therapy 2011; 16 Suppl 2:A31

The Metabolic Abnormalities, Telmisartan, and HIV Infection (MATH) Trial

JE Lake¹, CH Tseng¹, F Wu¹, JS Currier¹

¹University of California, Los Angeles, CA, USA

Background: Visceral adipose tissue (VAT) accumulation in the setting of HIV infection and ART is not fully understood, and treatment options remain limited. Telmisartan, an angiotensin receptor blocker and PPAR- γ agonist, has been shown to decrease VAT in HIV-uninfected subjects. This study examines the effects of standard-dose telmisartan on adipose tissue (AT) volumes and metabolic parameters in HIV-infected patients with lipohypertrophy.

Methods: 35 HIV-infected men and women with HIV-1 viral loads <48 copies/ml on ART and central fat accumulation (defined for women/men as: waist circumference $>94/95$ cm or a waist-to-hip ratio $>0.88/0.94$) received open-label telmisartan 40 mg daily for 24 weeks. AT volumes were quantified at 0 and 24 weeks by L4-L5 single slice CT scans. Waist circumference and waist:hip ratios were performed by a single operator using standardized technique. Fasting serum lipids, glucose and hs-CRP were obtained. 35 subjects provided 80% power to detect a 10% decrease in VAT over 24 weeks (two-sided alpha 0.05).

Results: 15 women and 20 men were enrolled and completed the 24-week protocol. At entry (mean or %): age 49; 43% Hispanic, 34% Black, 23% White; 91% non-smokers; CD4 635 cells/mm³; BMI 34.6; 51% PI, 20% NNRTI, 26% RAL, 74% TDF, 66% FTC. After 24 weeks, no significant improvement in VAT was observed, although participants lost a mean of 3.3% (95% CI -11.9%, 5.42%; $P=0.45$). A significant loss of both total (TAT; 4.2%; 95% CI -8.6, -0.21; $P=0.04$) and

subcutaneous (SAT; 3.4%; 95% CI -6.41%, -0.46%; $P=0.03$) AT was observed. A concomitant decrease in both waist and hip circumference accompanied SAT loss without an overall change in waist: hip ratio, VAT:TAT ratio, weight or BMI.

This study was not powered to detect differences between subgroups, however women lost 5.2% VAT ($P=0.48$), while men lost 1.9% ($P=0.73$). SAT and VAT loss was greater for subjects with BMI ≥ 30 at baseline (SAT: 5.6% vs 1.0%, $P=0.12$; VAT: 6.2% vs 0.02%, $P=0.49$).

No significant change in lipids, glucose or hs-CRP was observed. The average decrement in systolic/diastolic BP over 24 weeks was 7/5 mmHg, similar to that seen in HIV-negative subjects. No related Grade 3 or 4 adverse events occurred.

Conclusions: Telmisartan was extremely well-tolerated. No significant loss of VAT was demonstrated. However, an overall loss of VAT was observed, and greater losses may have been seen with continued follow-up. SAT loss has not been observed with telmisartan in the HIV-negative population. These findings warrant continued investigation of telmisartan's effects on AT depots in HIV-infected patients with lipodystrophy, including the potential for differential responses to treatment by sex.

ABSTRACT P09

Antiviral Therapy 2011; 16 Suppl 2:A31

Peripheral intermuscular adipose tissue and intramyocellular lipids: other fat compartments implicated in HIV-associated lipodystrophy changes seen on switching from thymidine analogues to tenofovir

A Milinkovic^{1,2}, AI García^{1,2}, R Sandoval^{1,2}, M del Amo^{1,2}, J Pomes^{1,2}, X Tomas^{1,2}, J Mallolas^{1,2}

¹Hospital Clinic, Barcelona, Spain; ²Biomedical Engineering Department, University of Barcelona, Spain

Background: Subcutaneous adipose tissue (SAT) decreases and that visceral abdominal fat (VAT) increases in HIV-associated lipodystrophy, measured by DEXA and CT scan. Decreased intermuscular adipose tissue (IMAT) and an elevation of intramyocellular lipid (IMCL) accumulation measured by magnetic resonance (MR) have also been described. No longitudinal studies have been reported evaluating any correlation between adipose tissue compartments, their association with metabolic parameters and the effects of switching from thymidine analogues (TA) to tenofovir disoproxil fumarate (TDF)-containing regimens.

Methods: 28 HIV-infected patients, 22 men and 6 women with moderate to severe lipodystrophy receiving